JP2005511499A - カゼイン由来ペプチドおよびその医療用途 - Google Patents

カゼイン由来ペプチドおよびその医療用途 Download PDF

Info

Publication number
JP2005511499A
JP2005511499A JP2003523265A JP2003523265A JP2005511499A JP 2005511499 A JP2005511499 A JP 2005511499A JP 2003523265 A JP2003523265 A JP 2003523265A JP 2003523265 A JP2003523265 A JP 2003523265A JP 2005511499 A JP2005511499 A JP 2005511499A
Authority
JP
Japan
Prior art keywords
peptide
casein
pharmaceutical composition
derived
terminal part
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003523265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511499A5 (hu
Inventor
ズヴィ シデルマン，
Original Assignee
チャイ １３ メディカル リサーチ グループ エヌ． ヴイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/942,121 external-priority patent/US20020147144A1/en
Application filed by チャイ １３ メディカル リサーチ グループ エヌ． ヴイ． filed Critical チャイ １３ メディカル リサーチ グループ エヌ． ヴイ．
Publication of JP2005511499A publication Critical patent/JP2005511499A/ja
Publication of JP2005511499A5 publication Critical patent/JP2005511499A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2003523265A 2001-08-30 2002-08-29 カゼイン由来ペプチドおよびその医療用途 Pending JP2005511499A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/942,121 US20020147144A1 (en) 2000-03-01 2001-08-30 Casein derived peptides and uses thereof in therapy
PCT/IL2002/000720 WO2003018606A2 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
JP2005511499A true JP2005511499A (ja) 2005-04-28
JP2005511499A5 JP2005511499A5 (hu) 2006-01-26

Family

ID=25477603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003523265A Pending JP2005511499A (ja) 2001-08-30 2002-08-29 カゼイン由来ペプチドおよびその医療用途

Country Status (15)

Country Link
EP (1) EP1556074A4 (hu)
JP (1) JP2005511499A (hu)
KR (1) KR20040078639A (hu)
CN (1) CN1694719A (hu)
AU (1) AU2002324323A2 (hu)
BR (1) BR0212625A (hu)
CA (1) CA2458924A1 (hu)
CZ (1) CZ2004335A3 (hu)
HU (1) HUP0500995A3 (hu)
IL (1) IL160548A0 (hu)
MX (1) MXPA04001890A (hu)
NO (1) NO20040880L (hu)
PL (1) PL375113A1 (hu)
WO (1) WO2003018606A2 (hu)
ZA (1) ZA200401574B (hu)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509073A (ja) * 2004-03-01 2008-03-27 ペプテラ ファーマスーティカルズ エルティーディー． カゼイン由来ペプチドおよびその治療的使用
JP2011026213A (ja) * 2009-07-22 2011-02-10 Snow Brand Milk Prod Co Ltd １型糖尿病抑制ペプチド
JP2015520129A (ja) * 2012-04-16 2015-07-16 ザ クリーブランド クリニック ファウンデーション 多価乳がんワクチン
WO2018159546A1 (ja) * 2017-03-03 2018-09-07 森永乳業株式会社 Ｇｌｐ－１分泌促進剤及び組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
US20050192312A1 (en) * 2004-01-30 2005-09-01 Brown Dennis M. Naphthalimide dosing by N-acetyl transferase genotyping
GB0423352D0 (en) 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
ES2319475B1 (es) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
JP4394155B2 (ja) 2006-06-09 2010-01-06 森永乳業株式会社 脂質代謝改善剤
CN107814835B (zh) * 2017-12-01 2020-04-28 熊猫乳品集团股份有限公司 一种生物活性多肽avpitptlnreq及其制备方法和应用
CN108017709B (zh) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽kepmigvnqela及其制备方法和应用
CN113952446B (zh) * 2021-09-03 2023-12-05 河南省医药科学研究院 生物活性肽在抑制骨髓毒性中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
EP0922769A4 (en) * 1997-03-21 2000-07-12 Snow Brand Milk Products Co Ltd HYDROLYSATE OF THE IRON-CASE COMPLEX AND A METHOD FOR ITS PRODUCTION.
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509073A (ja) * 2004-03-01 2008-03-27 ペプテラ ファーマスーティカルズ エルティーディー． カゼイン由来ペプチドおよびその治療的使用
JP2011026213A (ja) * 2009-07-22 2011-02-10 Snow Brand Milk Prod Co Ltd １型糖尿病抑制ペプチド
JP2015520129A (ja) * 2012-04-16 2015-07-16 ザ クリーブランド クリニック ファウンデーション 多価乳がんワクチン
WO2018159546A1 (ja) * 2017-03-03 2018-09-07 森永乳業株式会社 Ｇｌｐ－１分泌促進剤及び組成物
JPWO2018159546A1 (ja) * 2017-03-03 2019-12-26 森永乳業株式会社 Ｇｌｐ−１分泌促進剤及び組成物
JP7157043B2 (ja) 2017-03-03 2022-10-19 森永乳業株式会社 Ｇｌｐ－１分泌促進剤及び組成物

Also Published As

Publication number Publication date
AU2002324323A2 (en) 2003-03-10
WO2003018606A3 (en) 2005-05-06
NO20040880L (no) 2004-04-20
HUP0500995A3 (en) 2008-09-29
PL375113A1 (en) 2005-11-28
CN1694719A (zh) 2005-11-09
WO2003018606A2 (en) 2003-03-06
KR20040078639A (ko) 2004-09-10
IL160548A0 (en) 2004-07-25
BR0212625A (pt) 2007-06-19
HUP0500995A2 (en) 2007-05-02
EP1556074A4 (en) 2008-05-07
EP1556074A2 (en) 2005-07-27
CZ2004335A3 (cs) 2004-07-14
ZA200401574B (en) 2007-02-28
CA2458924A1 (en) 2003-03-06
MXPA04001890A (es) 2004-06-18
WO2003018606A9 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
JP2003528827A (ja) カゼイン由来ペプチドおよびその医療用途
JP2008509073A (ja) カゼイン由来ペプチドおよびその治療的使用
JP2005511499A (ja) カゼイン由来ペプチドおよびその医療用途
US7666996B2 (en) Casein derived peptides and uses thereof
JPH10502371A (ja) リンホトキシンを用いる癌処置法
EP1790355B1 (en) Propagation agent and propagation method for natural killer cell
JP2004508412A (ja) 抗新生物薬および免疫刺激薬としてのチオニン
TWI658832B (zh) 用於抑制骨髓衍生抑制細胞之組成物
NZ576636A (en) A method for screening for a substance having an action of proliferating natural killer cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060822

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090421